KLRG1, Another Opportunity for a Breakthrough in MTCL

Clin Cancer Res. 2024 Apr 3. doi: 10.1158/1078-0432.CCR-24-0374. Online ahead of print.ABSTRACTOutcomes in mature T-cell lymphomas remain poor, with previous attempts at developing monoclonal antibodies (mAb) compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T-cells and avoid the toxicity concerns with previous agents.PMID:38568191 | DOI:10.1158/1078-0432.CCR-24-0374
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research